Sonopharmaceuticals Inc.

sonopharmaceuticals inc. is a start-up drug-device company developing innovative approaches to manage cancer through ultrasound activated drugs, based in toronto, ontario. the company recently won the first prize in the ‘2009 healthcare & biotechnology venture challenge’, a business plan competition sponsored by sanofi pasteur. sono pharmaceuticals inc. is a pioneer in immuno-sonodynamic therapy (sdt), a unique technology platform involving a non-toxic family of ultrasound-sensitive, small molecular weight compounds. the dual technology attacks cancer on two fronts. firstly, ultrasound activation of this compound can produce toxic radicals directly inside the tumor cells. secondly, immuno-sdt can potentially induce an anti-tumor response from the patient’s own immune system to identify and eliminate local and distant metastases. tumor selectivity is achieved through the selective application of ultrasound. benefits: the two-pronged approach can potentially lead to long-term tumor contr